Natalizumab Treatment Modulates Peroxisome Proliferator-Activated Receptors Expression in Women with Multiple Sclerosis
Peroxisome Proliferator-Activated Receptors (PPAR) are transcription factors suggested to be involved in inflammatory lesions of autoimmune encephalomyelitis and multiple sclerosis (MS). Our objective was to assess whether Natalizumab (NTZ) therapy is associated with alterations of PPAR expression i...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | PPAR Research |
| Online Access: | http://dx.doi.org/10.1155/2016/5716415 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832563326584881152 |
|---|---|
| author | Véronique Ferret-Sena Alexandra Maia e Silva Armando Sena Inês Cavaleiro José Vale Bruno Derudas Giulia Chinetti-Gbaguidi Bart Staels |
| author_facet | Véronique Ferret-Sena Alexandra Maia e Silva Armando Sena Inês Cavaleiro José Vale Bruno Derudas Giulia Chinetti-Gbaguidi Bart Staels |
| author_sort | Véronique Ferret-Sena |
| collection | DOAJ |
| description | Peroxisome Proliferator-Activated Receptors (PPAR) are transcription factors suggested to be involved in inflammatory lesions of autoimmune encephalomyelitis and multiple sclerosis (MS). Our objective was to assess whether Natalizumab (NTZ) therapy is associated with alterations of PPAR expression in MS patients. We analyzed gene expression of PPAR in peripheral blood mononuclear cells (PBMC) as well as blood inflammatory markers in women with MS previously medicated with first-line immunomodulators (baseline) and after NTZ therapy. No differences in PPARα, PPARβ/δ, PPARγ, and CD36 mRNA expression were found in PBMC between patients under baseline and healthy controls. At three months, NTZ increased PPARβ/δ mRNA (p=0.009) in comparison to baseline, while mRNA expression of PPARγ and CD36 (a well-known PPAR target gene) was lower in comparison to healthy controls (p=0.026 and p=0.028, resp.). Although these trends of alterations remain after six months of therapy, the results were not statistically significant. Osteopontin levels were elevated in patients (p=0.002) and did not change during the follow-up period of NTZ treatment. These results suggest that PPAR-mediated processes may contribute to the mechanisms of action of NTZ therapy. |
| format | Article |
| id | doaj-art-ef2c1533643f4dd29315d0e5d7100e3c |
| institution | Kabale University |
| issn | 1687-4757 1687-4765 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | PPAR Research |
| spelling | doaj-art-ef2c1533643f4dd29315d0e5d7100e3c2025-02-03T01:20:29ZengWileyPPAR Research1687-47571687-47652016-01-01201610.1155/2016/57164155716415Natalizumab Treatment Modulates Peroxisome Proliferator-Activated Receptors Expression in Women with Multiple SclerosisVéronique Ferret-Sena0Alexandra Maia e Silva1Armando Sena2Inês Cavaleiro3José Vale4Bruno Derudas5Giulia Chinetti-Gbaguidi6Bart Staels7Interdisciplinary Centre of Research Egas Moniz (CiiEM), Caparica, PortugalInterdisciplinary Centre of Research Egas Moniz (CiiEM), Caparica, PortugalInterdisciplinary Centre of Research Egas Moniz (CiiEM), Caparica, PortugalInterdisciplinary Centre of Research Egas Moniz (CiiEM), Caparica, PortugalDepartment of Neurology, Hospital Beatriz Angelo, Loures, PortugalUniversity of Lille, Inserm, CHU Lille, Institut Pasteur de Lille, Lille, FranceUniversity of Lille, Inserm, CHU Lille, Institut Pasteur de Lille, Lille, FranceUniversity of Lille, Inserm, CHU Lille, Institut Pasteur de Lille, Lille, FrancePeroxisome Proliferator-Activated Receptors (PPAR) are transcription factors suggested to be involved in inflammatory lesions of autoimmune encephalomyelitis and multiple sclerosis (MS). Our objective was to assess whether Natalizumab (NTZ) therapy is associated with alterations of PPAR expression in MS patients. We analyzed gene expression of PPAR in peripheral blood mononuclear cells (PBMC) as well as blood inflammatory markers in women with MS previously medicated with first-line immunomodulators (baseline) and after NTZ therapy. No differences in PPARα, PPARβ/δ, PPARγ, and CD36 mRNA expression were found in PBMC between patients under baseline and healthy controls. At three months, NTZ increased PPARβ/δ mRNA (p=0.009) in comparison to baseline, while mRNA expression of PPARγ and CD36 (a well-known PPAR target gene) was lower in comparison to healthy controls (p=0.026 and p=0.028, resp.). Although these trends of alterations remain after six months of therapy, the results were not statistically significant. Osteopontin levels were elevated in patients (p=0.002) and did not change during the follow-up period of NTZ treatment. These results suggest that PPAR-mediated processes may contribute to the mechanisms of action of NTZ therapy.http://dx.doi.org/10.1155/2016/5716415 |
| spellingShingle | Véronique Ferret-Sena Alexandra Maia e Silva Armando Sena Inês Cavaleiro José Vale Bruno Derudas Giulia Chinetti-Gbaguidi Bart Staels Natalizumab Treatment Modulates Peroxisome Proliferator-Activated Receptors Expression in Women with Multiple Sclerosis PPAR Research |
| title | Natalizumab Treatment Modulates Peroxisome Proliferator-Activated Receptors Expression in Women with Multiple Sclerosis |
| title_full | Natalizumab Treatment Modulates Peroxisome Proliferator-Activated Receptors Expression in Women with Multiple Sclerosis |
| title_fullStr | Natalizumab Treatment Modulates Peroxisome Proliferator-Activated Receptors Expression in Women with Multiple Sclerosis |
| title_full_unstemmed | Natalizumab Treatment Modulates Peroxisome Proliferator-Activated Receptors Expression in Women with Multiple Sclerosis |
| title_short | Natalizumab Treatment Modulates Peroxisome Proliferator-Activated Receptors Expression in Women with Multiple Sclerosis |
| title_sort | natalizumab treatment modulates peroxisome proliferator activated receptors expression in women with multiple sclerosis |
| url | http://dx.doi.org/10.1155/2016/5716415 |
| work_keys_str_mv | AT veroniqueferretsena natalizumabtreatmentmodulatesperoxisomeproliferatoractivatedreceptorsexpressioninwomenwithmultiplesclerosis AT alexandramaiaesilva natalizumabtreatmentmodulatesperoxisomeproliferatoractivatedreceptorsexpressioninwomenwithmultiplesclerosis AT armandosena natalizumabtreatmentmodulatesperoxisomeproliferatoractivatedreceptorsexpressioninwomenwithmultiplesclerosis AT inescavaleiro natalizumabtreatmentmodulatesperoxisomeproliferatoractivatedreceptorsexpressioninwomenwithmultiplesclerosis AT josevale natalizumabtreatmentmodulatesperoxisomeproliferatoractivatedreceptorsexpressioninwomenwithmultiplesclerosis AT brunoderudas natalizumabtreatmentmodulatesperoxisomeproliferatoractivatedreceptorsexpressioninwomenwithmultiplesclerosis AT giuliachinettigbaguidi natalizumabtreatmentmodulatesperoxisomeproliferatoractivatedreceptorsexpressioninwomenwithmultiplesclerosis AT bartstaels natalizumabtreatmentmodulatesperoxisomeproliferatoractivatedreceptorsexpressioninwomenwithmultiplesclerosis |